Answers are grounded in this paper and cite their sources.
Observational analysis found elevated EMAP-II levels in diabetic retinopathy stages, suggesting it as a blood biomarker.
Background. Endothelial dysfunction is involved in the pathogenesis of microvascular complications of type 2 diabetes mellitus. Endothelial monocyte-activating polypeptide-II (EMAP-II) is a multifunctional polypeptide with proinflammatory and antiangiogenic activity, which is associated with the development of diabetic retinopathy (DR). Aim: to determine the blood content of EMAP-II at different stages of DR and the possibility of its use as a biomarker of DR progression. Material and methods. 136 patients with type 2 diabetes were examined, who were divided into groups: 1st - with non-proliferative (NPDR, 60 eyes), 2nd - with preproliferative DR (PPDR; 42 eyes) and 3rd - with proliferative DR (PDR; 34 eyes). Patients were examined and treated for 2 years. 25 patients who did not have diabetes were involved as controls. EMAP-II was determined in blood serum by enzyme-linked immunosorbent assay. Analysis of the study results was carried out in the EZR v.1.54 package (Austria). Results. In patients with DR and type 2 diabetes, a significant increase in the blood content of EMAP-II was found compared to the control. In NPDR, it exceeded the control level by 2.5 times, in PPDR – by 4.6 times, in PDR – by 6.1 times (p<0.001 for all comparisons). Intergroup comparisons were also statistically significant (p<0.05), which confirmed the progressive nature of the increase in EMAP-II in the DR development. The cut-off levels of EMAP-II were determined: for NPDR they were from 2.186 ng/ml to 5.66 ng/ml, in PPDR – from 5.67 ng/ml to 7.565 ng/ml and in PDR – more than 7.565 ng/ml. The overall prediction accuracy was 82.0% (95% CI 75.2-87.6%). EMAP-II levels were significantly correlated with fasting blood glucose (r=0.207), central retinal thickness (r=0.578) and volume (r=0.554), glycated hemoglobin (r=0.699), total cholesterol (r=0.442), high-density lipoprotein (r=0.25), low-density lipoprotein (r=0.39) and very low-density lipoprotein (r=0.515), and triglycerides (r=0.359; p<0.05 for all cases). The risk of DR progression after 2 years of observation increased 2.0-fold with increasing EMAP-II levels in the blood (p<0.001; OR=2.0; 95% CI 1.6-2.49). The area under the curve of the operating characteristics of the prediction AUC=0.88 (95% CI 0.81-0.93), the sensitivity of the model was 70.9%, specificity – 89.5%. Conclusion. Thus, it was established that EMAP-II is one of key factor in the DR pathogenesis, which is closely related to phenotypic manifestations, and its content in the blood is a biomarker of the stage of DR and its progression.
No takes yet. Share an insight, caveat, or question.
A.V. Serdiuk (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: